[{"id":"24f1d946-73ba-49c0-a984-94bc11118b09","acronym":"","url":"https://clinicaltrials.gov/study/NCT06865443","created_at":"2025-09-07T01:53:03.055Z","updated_at":"2025-09-07T01:53:03.055Z","phase":"","brief_title":"Evaluation of CD47, \"Do Not Eat Me\" Signal Expression in Chronic Myeloid Leukemia","source_id_and_acronym":"NCT06865443","lead_sponsor":"Assiut University","biomarkers":" CD47","pipe":"","alterations":" ","tags":["CD47"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-03-07"},{"id":"5ba9d628-6d23-4d5d-9027-4c4a55c8330e","acronym":"NCI-2019-08626","url":"https://clinicaltrials.gov/study/NCT04214249","created_at":"2024-01-11T17:17:48.143Z","updated_at":"2025-02-25T17:00:21.915Z","phase":"Phase 2","brief_title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04214249 - NCI-2019-08626","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"da2b0979-fceb-4b41-a878-bc533fb0df47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807126","created_at":"2023-04-11T14:03:25.975Z","updated_at":"2024-07-02T16:35:06.439Z","phase":"Phase 1","brief_title":"Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations","source_id_and_acronym":"NCT05807126","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3","pipe":" | ","alterations":" HR positive • BRCA mutation • CD47 expression","tags":["IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRCA mutation • CD47 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • magrolimab (ONO-7913)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 12/06/2026","primary_completion_date":" 12/06/2026","study_txt":" Completion: 12/06/2026","study_completion_date":" 12/06/2026","last_update_posted":"2024-05-02"},{"id":"f5ce5e9d-2a3d-4cf4-9915-fcca832b827b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05277753","created_at":"2022-03-14T14:54:15.233Z","updated_at":"2024-07-02T16:36:15.399Z","phase":"Phase 1","brief_title":"NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL","source_id_and_acronym":"NCT05277753","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD38 • CD47 • CD5 • CD7","pipe":"","alterations":" ","tags":["CD38 • CD47 • CD5 • CD7"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-15"},{"id":"ce929a69-a621-47c8-a567-6114397ddcd4","acronym":"MDScan","url":"https://clinicaltrials.gov/study/NCT02868255","created_at":"2021-01-18T14:04:45.610Z","updated_at":"2024-07-02T16:36:24.555Z","phase":"","brief_title":"Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma","source_id_and_acronym":"NCT02868255 - MDScan","lead_sponsor":"Nantes University Hospital","biomarkers":" CD47 • SIRPA","pipe":" | ","alterations":" CD47 expression","tags":["CD47 • SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD47 expression"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/03/2016","start_date":" 01/03/2016","primary_txt":" Primary completion: 11/30/2018","primary_completion_date":" 11/30/2018","study_txt":" Completion: 11/30/2018","study_completion_date":" 11/30/2018","last_update_posted":"2021-09-13"},{"id":"39b20fa2-7752-4a7c-b6f5-2260380107ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT01410981","created_at":"2021-01-18T05:48:20.512Z","updated_at":"2024-07-02T16:37:11.821Z","phase":"","brief_title":"Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma","source_id_and_acronym":"NCT01410981","lead_sponsor":"Medical University of South Carolina","biomarkers":" CXCR4 • CD47","pipe":"","alterations":" ","tags":["CXCR4 • CD47"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2018-04-05"}]